Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents.

about

Saliva as a Future Field in Psoriasis Research.

P2860

Q55057884-2F31A66C-2CEA-4623-ADA7-A3CE6971743E

P2860

Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents.

Item

http://www.wikidata.org/entity/Q52661693

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Outcomes assessment of hepatit ...... irect-Acting Antiviral agents.

@en

Outcomes assessment of hepatit ...... irect-Acting Antiviral agents.

@nl

type

Item

label

Outcomes assessment of hepatit ...... irect-Acting Antiviral agents.

@en

Outcomes assessment of hepatit ...... irect-Acting Antiviral agents.

@nl

prefLabel

Outcomes assessment of hepatit ...... irect-Acting Antiviral agents.

@en

Outcomes assessment of hepatit ...... irect-Acting Antiviral agents.

@nl

P1476

Outcomes assessment of hepatit ...... Direct-Acting Antiviral agents

@en

P2093

Andrea Altomare

http://www.w3.org/2001/XMLSchema#string

Chiara Franchi

http://www.w3.org/2001/XMLSchema#string

Maria Caterina Pace

http://www.w3.org/2001/XMLSchema#string

Paolo Pigatto

http://www.w3.org/2001/XMLSchema#string

Sebastiano Leone

http://www.w3.org/2001/XMLSchema#string

Stephen Petrou

http://www.w3.org/2001/XMLSchema#string

P2860

New approaches in the treatment of hepatitis C

Management of psoriasis patients with hepatitis B or hepatitis C virus infection

Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases.

Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis

Safety and efficacy of anti-tumor necrosis factors α in patients with psoriasis and chronic hepatitis C

A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin.

Incidence and risk factors for psoriasis in the general population.

To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis.

Blood to skin recirculation of CD4+ memory T cells associates with cutaneous and systemic manifestations of psoriatic disease.

Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature.

P304

329-336

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4254/WJH.V10.I2.329

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

G Damiani

Alessia Pacifico

M Fiore

P577

2018-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29527268

http://www.w3.org/2001/XMLSchema#string

P932

5838451

http://www.w3.org/2001/XMLSchema#string

Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents.

about

P2860

P2860

Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932